AdventHealth Cancer Institute, Orlando, FL
Mark A. Socinski, Leigh Boehmer
Background: While clinical guidelines for non-small cell lung cancer (NSCLC) provide recommendations on individual components of care and advocate multidisciplinary collaboration, guidance spanning the complete patient journey is lacking. We aimed to compile quality-focused recommendations for the multidisciplinary team and selected clinical criteria for ideal NSCLC care, and propose a new set of metrics encompassing the entire care continuum. These metrics would be used as a new benchmark for ideal NSCLC care via the Association of Community Cancer Centers’ (ACCC) national quality care initiative for patients with advanced (stage III/IV) NSCLC. Methods: The ACCC convened an expert steering committee of multidisciplinary specialists and representation from patient advocacy to compile evidence-based recommendations via a systematic search of clinical and quality care guidelines and peer-reviewed journals. Quality recommendations were organized within key care areas of the patient journey: care coordination and patient education, diagnosis and biomarker testing, staging and treatment planning, and survivorship. Results: A total of 32 recommendations were included across the 4 key NSCLC care areas. Key quality recommendations are listed (Table). Conclusions: The full set of recommendations define ideal NSCLC care and serve as a valuable guide for multidisciplinary practice and quality improvement initiatives.
Care coordination and patient education | Diagnosis and biomarker testing | Staging and treatment planning | Survivorship |
---|---|---|---|
· Standardize patient participation in shared decision-making · Educate patients on all aspects of NSCLC management, including diagnosis, staging, and treatment · Provision of access to an MDT care navigator for information on financial aspects of treatment | · Multidisciplinary evaluation of suspicious findings · MDT coordination for efficient biopsy collection · Use of broad molecular profiling to identify actionable and rare mutations | · Incorporation of invasive staging procedures for increased sensitivity and specificity · Staging and use of appropriate techniques is paramount to define treatment planning · Biomarker tests to inform all treatment-related decisions · Repeat biopsy and/or plasma testing in the setting of insufficient tissue | · Implementation of standard protocols for short- and long-term surveillance · Provision of survivorship care plans to all patients diagnosed with advanced NSCLC |
MDT, multidisciplinary team; NSCLC, non-small cell lung cancer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2020 ASCO Virtual Scientific Program
First Author: Mark A. Socinski
2022 ASCO Quality Care Symposium
First Author: Matthew Smeltzer
2023 ASCO Quality Care Symposium
First Author: Laura LaNiel Tenner
2023 ASCO Quality Care Symposium
First Author: Matthew Rice